PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33025946-3	2020	This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX.	Methotrexate	151-163	Janus kinase 1	Homo sapiens	5-8	
34480250-6	2022	Western blot and qRT-PCR analysis suggested that treatment with methotrexate (MTx) dampened CoV-2-SRBD-mediated increase in JAK1/STAT3 phosphorylation, gp130, IL6, and folate-binding protein (FBP) expressions.	Methotrexate	64-76	Janus kinase 1	Homo sapiens	124-128	
34480250-6	2022	Western blot and qRT-PCR analysis suggested that treatment with methotrexate (MTx) dampened CoV-2-SRBD-mediated increase in JAK1/STAT3 phosphorylation, gp130, IL6, and folate-binding protein (FBP) expressions.	Methotrexate	78-81	Janus kinase 1	Homo sapiens	124-128	
33025946-3	2020	This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX.	Methotrexate	165-168	Janus kinase 1	Homo sapiens	5-8	
33025946-3	2020	This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX.	Methotrexate	205-208	Janus kinase 1	Homo sapiens	5-8	
31313387-4	2019	MTX has also been shown to exert JAK inhibition of JAK2 and JAK1 when tested in Drosophila melanogaster as a model of kinase activity and in human cell lines (nodular sclerosis Hodgkin"s lymphoma and acute myeloid leukemia cell lines).	Methotrexate	0-3	Janus kinase 1	Homo sapiens	60-64	
31313387-5	2019	These effects may explain why MTX leads to clinical effects similar to anti-TNFalpha biologics in monotherapy, but is less effective when compared to anti-IL6R in monotherapy, which acting upstream exerts major effects downstream on the JAK1-STAT3 pathway.	Methotrexate	30-33	Janus kinase 1	Homo sapiens	237-241	
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	4-7	Janus kinase 1	Homo sapiens	19-23	
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	4-7	Janus kinase 1	Homo sapiens	114-118	
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	4-7	Janus kinase 1	Homo sapiens	114-118	
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	4-7	Janus kinase 1	Homo sapiens	114-118	
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	89-92	Janus kinase 1	Homo sapiens	19-23